Edition:
India

Fluidigm Corp (FLDM.OQ)

FLDM.OQ on NASDAQ Stock Exchange Global Select Market

4.73USD
18 Oct 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.73
Open
$4.59
Day's High
$4.84
Day's Low
$4.58
Volume
282,337
Avg. Vol
289,987
52-wk High
$14.88
52-wk Low
$4.03

Summary

Name Age Since Current Position

Samuel Colella

79 2000 Independent Chairman of the Board

Stephen Linthwaite

47 2016 President, Chief Executive Officer, Director

Vikram Jog

62 2018 Chief Financial Officer, Principal Accounting Officer

Nicholas Khadder

45 2016 Senior Vice President, General Counsel, Corporate Secretary

Bradley Kreger

44 2018 Senior Vice President, Global Operations

Nicolas Barthelemy

53 2017 Independent Director

Gerhard Burbach

57 2013 Independent Director

Laura Clague

60 2018 Independent Director

Bill Colston

2019 Independent Director

Patrick Jones

74 2011 Independent Director

Carlos Paya

60 2017 Independent Director

Biographies

Name Description

Samuel Colella

Mr. Samuel D. Colella is an Independent Chairman of the Board of Fluidigm Corporation since July 2000. Mr. Colella is a managing director of Versant Ventures, a healthcare venture capital firm he co-founded in 1999, and has been a general partner of Institutional Venture Partners since 1984. Mr. Colella currently serves on the board of directors of Flexion Therapeutics, Inc., a specialty pharmaceutical company. Mr. Colella also is currently a member of the board of directors of several private companies. Mr. Colella served on the board of directors of Genomic Health, Inc., a molecular diagnostics company, from 2001 to 2014; Alexza Pharmaceuticals, Inc., a pharmaceutical company, from 2002 to 2012; Jazz Pharmaceuticals, Inc., a biopharmaceutical company, from 2003 to 2012; Veracyte, Inc., a diagnostics company, from 2006 to 2014. Mr. Colella received a B.S. in business and engineering from the University of Pittsburgh and an M.B.A. from Stanford University

Stephen Linthwaite

Mr. Stephen Christopher Linthwaite serves as President, Chief Executive Officer, Director of the Company. From August 2003 to April 2016, Mr. Linthwaite held various managerial positions at Thermo Fisher Scientific Inc., a life sciences company, and prior to its acquisition by Thermo Fisher, at Life Technologies Corporation, a life sciences company, including president, genetic sciences division, from December 2014 to April 2016, president, genetic analysis platform, from September 2011 to December 2014, and various other managerial positions at Invitrogen prior to the creation of Life Technologies through a merger of Invitrogen and Applied Biosystems. Prior to joining Invitrogen, Mr. Linthwaite held various strategic consulting roles. Mr. Linthwaite served on the board of directors of Claritas Genomics, Inc. from December 2014 to April 2016. Mr. Linthwaite received an M.B.A. from the University of Virginia (Darden) School of Business, and a B.A. in Foreign Affairs from the University of Virginia. Prior to business school, Mr. Linthwaite served on active duty in the U.S. Army as an armor officer.

Vikram Jog

Mr. Vikram Jog has been appointed as Chief Financial Officer, Principal Accounting Officer of Fluidigm Corporation., effective as of March 29, 2018. From April 2005 to February 2008, Mr. Jog served as chief financial officer for XDx, Inc. (now CareDx, Inc.), a molecular diagnostics company. From March 2003 to April 2005, Mr. Jog was a vice president of Applera Corporation, a life science company that is now part of Thermo Fisher Scientific, and vice president of finance for its related businesses, Celera Genomics and Celera Diagnostics. From April 2001 to March 2003, Mr. Jog was vice president of finance for Celera Diagnostics and corporate controller of Applera Corporation. Mr. Jog received a Bachelor of Commerce degree from Delhi University and an M.B.A. from Temple University. Mr. Jog is a member of the American Institute of Certified Public Accountants.

Nicholas Khadder

Mr. Nicholas Khadder has served as our Senior Vice President, General Counsel, and Corporate Secretary since June 2016. From 2010 to June 2016, Mr. Khadder held various positions at Amyris, Inc., an industrial biotechnology company, including senior vice president, general counsel and corporate secretary from 2013 to June 2016, interim general counsel from July 2013 to December 2013 and assistant general counsel from October 2010 to July 2013. Prior to joining Amyris, Mr. Khadder served in senior corporate counsel roles at LeapFrog Enterprises, Inc., an educational entertainment company, from August 2008 to September 2010, and at Protiviti, Inc., an internal audit and risk consulting firm, from June 2005 to July 2008. Before commencing his in-house legal career, Mr. Khadder was a corporate law associate at Fenwick & West LLP from 1998 to 2005. Mr. Khadder received a J.D. from Berkeley Law (the University of California, Berkeley, School of Law) and a B.A. in English from the University of California, Berkeley.

Bradley Kreger

Mr. Bradley Kreger is Senior Vice President, Global Operations of the Company. From December 2016 to April 2018, Mr. Kreger was Senior Director, Operations, Clinical Sequencing Division at Thermo Fisher Scientific, a life sciences company. From 1995 to December 2016, Mr. Kreger held various staff and management positions at Affymetrix, a biotechnology company, including VP, Reagent Manufacturing & Global Process Engineering, Senior Director, Global Process Engineering and Manufacturing Science, and Director, Global Process Engineering and Manufacturing Science. Mr. Kreger received a MBA from Western Governors University and a B.S. in Biotechnology and Business from Charter Oak State College.

Nicolas Barthelemy

Mr. Nicolas M. Barthelemy is Director of the Company. Mr. Barthelemy brings over 25 years of health-care industry experience to the director role. From 2014 to February 2017, Mr. Barthelemy served as the president and chief executive officer of Biotheranostics, Inc., a molecular diagnostics company. From 2010 until 2013, he served as president, global commercial operations at Life Technologies Corporation, a global life sciences company, which was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that position, he led the $850M Cell Systems division from 2005 to 2010. Before Life Technologies, from 1996 to 2004, Mr. Barthelemy was with Biogen Inc., a biotechnology company, most recently as vice president, manufacturing. He began his career with Merck & Co., Inc., a pharmaceutical company, as a project engineer in the vaccine division and worked for the company from 1991 to 1996. From January 2018 to November 2018, Mr. Barthelemy served on the board of directors of Genewiz (privately held), a biotechnology company. Mr. Barthelemy currently serves as a member of the boards of directors of Repligen Corporation, 908 Devices Inc. (privately held), and of Biocare Medical, LLC (privately held). All three companies are in the life sciences sector. He received an M.S. in Chemical Engineering from the University of California, Berkeley in 1991, and an engineering degree from Ecole Superieure de Physique et Chimie Industrielles, Paris in 1989.

Gerhard Burbach

Mr. Gerhard F. Burbach is Independent Director of Fluidigm Corporation . Mr. Burbach currently serves as chairman of the board of directors of Procyrion Inc., a private medical device company focused on the treatment of chronic heart failure, and as a member of the boards of directors of Vascular Dynamics, a private medical device company focused on the treatment of hypertension, and BWX Technologies, Inc., a company that manufactures and supplies nuclear components and fuel. Mr. Burbach received a B.S. in Industrial Engineering from Stanford University in 1984 and an M.B.A. from Harvard business School in 1990.

Laura Clague

Ms. Laura M. Clague serves as Director of the company. Ms. Clague has served as the Senior Vice President and Chief Financial Officer of Retrophin, Inc. since November 2014. Ms. Clague previously served as the Chief Financial Officer of the San Diego and Ohio operations of Amylin Pharmaceuticals, Inc., a wholly owned subsidiary of Bristol-Myers Squibb. Prior to the acquisition by Bristol-Myers Squibb in 2012, Ms. Clague was the Vice President, Corporate Controller and Chief Accounting Officer of Amylin for 10 years, and during this time also served as the Chief Financial Officer of the Amylin/Lilly Collaboration. From 1988 to 1999, Ms. Clague was the director of finance and accounting operations for Sony Electronics, Inc. From 1985 to 1988, Ms. Clague served as internal audit supervisor at Cubic Corporation. From 1982 to 1985, Ms. Clague held various audit positions at KPMG. Ms. Clague also serves on the Board of Directors of LRAD Corporation where she chairs the Audit Committee. Ms. Clague is a certified public accountant in the State of California, and has a B.S. in Business Administration from Menlo College.

Bill Colston

Dr. Bill W. Colston, Jr. Ph.D., serves as Director of the Company. Colston is President of iCarbonX and has more than 30 years of experience across a range of innovative life science and technology ventures. Colston has served as President of personal health company iCarbonX since March 2019. He joined iCarbonX as Chief Operating Officer in April 2018, following its acquisition of his prior company, and is a member of its Board of Directors. Previously, he was a co-founder and Chief Executive Officer of HealthTell Inc., a company focused on developing next-generation tests that broadly characterize the immune system. He was also scientific founder and CEO of QuantaLife Inc., which developed a genetic analysis system that is now marketed internationally. Colston began his career at Lawrence Livermore National Laboratory, where he served in various senior leadership roles over a nearly 20-year career and helped build the first civilian biodefense program in the United States. Colston is also a board member of companies including Purigen Biosystems and RubrYc Therapeutics. He holds a PhD in biomedical engineering from the University of California, Davis.

Patrick Jones

Mr. Patrick S. Jones is an Independent Director of Fluidigm Corporation since March 2011. Mr. Jones has been a private investor since March 2001. Mr. Jones currently serves on the board of directors of Talend SA, a data integration software company, and Itesoft SA, a business process automation software company. From 2003 to May 2018, Mr. Jones served as chairman of Inside Secure SA, a company that makes digital security solutions. From 2005 to May 2015, Mr. Jones served on the board of directors of Lattice Semiconductor Corporation, a fabless semiconductor company. From 2012 to 2013, Mr. Jones served as chairman of Dialogic Inc., a communications technology company. From 2005 to 2012, Mr. Jones served as chairman of Epocrates, Inc., a provider of clinical solutions to healthcare professionals and interactive services to the healthcare industry, which was acquired by athenahealth, Inc. in 2013. From 2007 to 2012, Mr. Jones also served on the board of directors of Openwave Systems Inc., a telecom infrastructure software provider that changed its name to Unwired Planet in 2012. From 2007 to 2011, Mr. Jones served on the board of directors of Novell, Inc., an enterprise infrastructure software provider that was sold to Attachmate Corporation in 2011. From June 1998 to March 2001, Mr. Jones was the senior vice president and chief financial officer of Gemplus International S.A., a provider of solutions empowered by smart cards. From March 1992 to June 1998, he was vice president of finance and corporate controller at Intel Corporation, a producer of microchips and communications products. Prior to that, Mr. Jones served as chief financial officer of LSI Corporation (formerly known as LSI Logic), a semiconductor company.

Carlos Paya

Dr. Carlos V. Paya, M.D., Ph.D., is Director of the Company. Since May 2011, Dr. Paya has served as president, chief executive officer and director of Immune Design Corp. He previously served as president of Elan Corporation, a pharmaceutical corporation, which was acquired by Perrigo Company, from November 2008 to April 2011. Before joining Elan Corporation, Dr. Paya was at Eli Lilly & Company, a pharmaceutical corporation, from September 2001 to November 2008, as vice president, Lilly Research Laboratories. From January 1991 to August 2001, Dr. Paya was professor of medicine, immunology, and pathology, and vice dean of the clinical investigation program at the Mayo Clinic in Rochester, Minnesota. He received his M.D. and Ph.D. degrees from the University of Madrid and underwent postdoctoral training at the Institute Pasteur, Paris, France.

Basic Compensation

Name Fiscal Year Total

Samuel Colella

164,777

Stephen Linthwaite

2,585,210

Vikram Jog

1,125,540

Nicholas Khadder

1,091,460

Bradley Kreger

995,197

Nicolas Barthelemy

124,777

Gerhard Burbach

132,775

Laura Clague

144,317

Bill Colston

--

Patrick Jones

127,782

Carlos Paya

112,779
As Of  31 Dec 2018